ABVC (ABVC BioPharma) Total Liabilities: $6.90 Mil (As of Mar. 2026)


ABVC ABVC BioPharma Inc ABVC
17 GF Score
Price $1.46
GF Value $0.87
Valuation Significantly Overvalued
! 1 Warning Sign
View Full Analysis

What is ABVC BioPharma Total Liabilities?

ABVC BioPharma ABVC +1.39% 17 Total Liabilities is $6.90 Mil as of Mar. 2026. GuruFocus rates ABVC with a GF Score™ of 17/100 and a GF Value™ of $0.87 (Significantly Overvalued). The stock has 1 warning sign investors should review.

ABVC BioPharma's Total Liabilities for the quarter that ended in Mar. 2026 was $6.90 Mil.

ABVC BioPharma's quarterly Total Liabilities increased from Sep. 2025 ($6.68 Mil) to Dec. 2025 ($7.77 Mil) but then declined from Dec. 2025 ($7.77 Mil) to Mar. 2026 ($6.90 Mil).

ABVC BioPharma's annual Total Liabilities increased from Dec. 2023 ($6.53 Mil) to Dec. 2024 ($6.82 Mil) and increased from Dec. 2024 ($6.82 Mil) to Dec. 2025 ($7.77 Mil).


ABVC BioPharma Total Liabilities Historical Data

* Premium members only.

The historical data trend for ABVC BioPharma's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ABVC BioPharma Total Liabilities Chart

ABVC BioPharma Annual Data
Trend Sep16 Sep17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.83 6.34 6.53 6.82 7.77

ABVC BioPharma Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.92 6.75 6.68 7.77 6.90
ABVC
17GF Score
ABVC BioPharma Inc ABVC
Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

ABVC BioPharma Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

ABVC BioPharma's Total Liabilities for the fiscal year that ended in Dec. 2025 is calculated as

Total Liabilities=Total Assets (A: Dec. 2025 )-Total Equity (A: Dec. 2025 )
=21.062-13.297
=7.77

ABVC BioPharma's Total Liabilities for the quarter that ended in Mar. 2026 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=5.393+(1.511+2.2204460492503E-16
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=6.90

Total Liabilities=Total Assets (Q: Mar. 2026 )-Total Equity (Q: Mar. 2026 )
=19.733-12.828
=6.91

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of $6.90 Mil mean?
ABVC BioPharma (ABVC) has a Total Liabilities of $6.90 Mil as of Mar. 2026. The total amount of liabilities as recorded on a company's balance sheet. View historical data for ABVC BioPharma and its competitors.
Is ABVC BioPharma's Total Liabilities too high?
ABVC BioPharma's current Total Liabilities is $6.90 Mil. Overall, ABVC BioPharma has a GF Score™ of 17/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does ABVC BioPharma's Total Liabilities compare to GRDX and INMB?
ABVC BioPharma's Total Liabilities of $6.90 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Biotechnology company?
A good Total Liabilities depends on the Biotechnology industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for ABVC BioPharma and its competitors. ABVC BioPharma's current Total Liabilities is $6.90 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ABVC BioPharma stock overvalued right now?
Based on GuruFocus' analysis, ABVC BioPharma (ABVC) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.87, compared to a current price of $1.46 — trading 67.8% above its estimated fair value. The current Total Liabilities is $6.90 Mil. ABVC BioPharma's overall GF Score™ is 17/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For ABVC BioPharma (ABVC), the current Total Liabilities is $6.90 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is ABVC BioPharma (ABVC) Overvalued in 2026?

Based on GuruFocus' analysis, ABVC BioPharma stock appears to be overvalued. The current stock price of $1.46 is trading 67.8% above its estimated GF Value™ of $0.87. GuruFocus considers ABVC BioPharma to be Significantly Overvalued.

Key valuation signals for ABVC:

  • Total Liabilities: $6.90 Mil
  • GF Value™: $0.87 vs. price of $1.46 (67.8% above fair value)
  • GF Score™: 17/100 with 1 warning sign

No single metric tells the full story. See the ABVC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


ABVC BioPharma Business Description

Address 44370 Old Warm Springs Boulevard, Fremont, CA, USA, 94538
ABVC BioPharma Inc is a clinical stage biopharmaceutical company focused on development of new drugs and medical devices, all of which are derived from plants. It currently has six drugs and three medical devices in development. The firm specializes in botanically based solutions that deliver high efficacy with low toxicity for improved health outcomes. Its products include: Vitargus - ABV-1701, ABV-2001, ABV-2002, MDD ABV-1504, ADHD ABV-1505, ADHD ABV-1601, ABV-1501, ABV-1702, and ABV-1703.
17GF Score

Get the complete analysis for ABVC

Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.46
Price
$0.87
GF Value